Biomedical Engineering Reference
In-Depth Information
drug delivery systems for the treatment of
retinal diseases: basic research to clinical
applications. IOVS 51(11):5403-5020.
doi:
10.1167/IOVS.10-5392
3. Lang JC (1995) Ocular drug delivery conven-
tional ocular formulations. Adv Drug Deliv
Rev 16:39-43
4. Yu LX (2008) Pharmaceutical quality by
design: product and process development,
understanding and control. Pharm Res 25
(4):781-791
5. Urtti A (2006) Challenges and obstacles of
ocular pharmacokinetics and drug delivery.
Adv Drug Deliv Rev 58:1131-1135
6. Davies NM (2000) Biopharmaceutical consid-
erations in topical ocular drug delivery. Clin
Exp Pharmacol Physiol 27:558-562
7. Kidron H, Vellonen K-S, del Amo EM, Tissari
A, Urtti A (2010) Prediction of the corneal
permeability of drug-like compounds. Pharm
Res 27(7):1398-407
8. Liaw J, Rojanasakul W, Rojanasakul JR (1992)
The effect of drug charge type and charge den-
sity on corneal transport in rabbits. Int J Pharm
88:111-124
9. Shirasaki Y (2008) Molecular design for
enhancement of ocular penetration. J Pharm
Sci 97(7):2462-2496. doi:
10.1002/jps.21200
10. Schoenwald RD, Ward WR (1978) Relation-
ship between steroid permeability across rabbit
cornea and octanol-water partition coefficients.
J Pharm Sci 67:786-788
11. Kishida K, Otori T (1980) A quantitative study
on the relationship between transcorneal per-
meability of drugs and their hydrophobicity.
Jpn J Ophthalmol 24:251-259
12. Schoenwald RD, Huang HS (1983) Corneal
penetration behavior of
analysis for drug delivery to the eye. J Pharm
Sci 87(12):1479-1488
18. Lee VHL, Robinson J (1986) Topical ocular
drug delivery: recent developments and future
challenges. J Occup Pharmacol 2(1):67-108
19. Fiscella RG (2008) Ophthalmic drug formula-
tions. In: Bartlett JD, Jaanus NL (eds) Clinical
ocular pharmacology, 5th edn. Elsevier, New
York, pp 17-37
20. Gibson M (2009) Ophthalmic dosage forms.
In: Gibson M (ed) Pharmaceutical preformula-
tion and formulation. Informa Healthcare,
New York, pp 431-455
21. Lee VHL, Li VHK (1989) Prodrugs for
improved ocular drug delivery. Adv Drug
Deliv Rev 3:1-38
22. Jarvinen T, Jarvinen K, (1996) Prodrugs for
improved ocular drug delivery. Adv Drug
Deliv Rev 19(2): 203-224, doi:
http://dx.
23. Tammara VK, Crider MA (1996) Prodrugs: a
chemical approach to drug delivery. In: Reddy
IK (ed) Ocular therapeutics and drug delivery.
Technomic, Lancaster, PA, pp 285-334
24. Kwatra D, Vaishya R, Gaudana R, Jwala J,
Mitra AK (2011) Ocular delivery using pro-
drugs. In: Rautio J (ed) Prodrugs and targeted
delivery, vol 47. Wiley-VCH, Weinheim,
pp 181-205
25. Barot M, Bagui M, Gokulgandhi MR, Mitra
AK (2012) Prodrug strategies in ocular drug
delivery. Med Chem 8(4):753-768
26. Niazi SK (ed) (2007) Handbook of preformu-
lation. Informa Healthcare, New York
27. Center for Drug Evaluation and Research
Guideline (1987) Submitting supporting doc-
umentation in drug applications for the manu-
facture of drug substances
28. Code of Federal Regulations, 21CFR314.50
(Revised 2012)
29. ICH Harmonized Tripartitite Guidelines
(2006) Guidance for industry, Q3A impurities
in new drug substances
30. ICH Harmonized Tripartitite Guidelines
(2009) Guidance to industry, Q8 (R2) phar-
maceutical development
31. ICH Harmonized Tripartitite Guidelines
(1998) Q6A specifications: test procedures
and acceptance criteria for new drug substances
and new drug products: chemical substances
32. Center for Drug Evaluation and Research
Guidance (2000) NDAs: impurities in drug
substances
33. ICH Harmonized Tripartitite Guidelines
(2006) Q3A (R2),
β
blocking agents I:
physicochemical
factors.
J
Pharm Sci
72:1266-1272
13. Huang AJ, Tseng SC, Kenyon KR (1989) Para-
cellular permeability of cornea and conjunctival
epithelia. IOVS 30(4):684-689
14. Schoenwald RD (1993) Ocular pharmacoki-
netics/pharmacodynamics. In: Mitra AK (ed)
Ophthalmic drug delivery system. Marcel
Decker, New York
15. Wang W, Sasaki H, Chien DS, Lee VHL
(1991) Liphophilicity influence on conjuctival
drug penetration in pigmented rabbit: a com-
parison with corneal penetration. Curr Eye Res
10:571-579
16. Burstein NL, Anderson JA (1985) Review: cor-
neal penetration and ocular bioavailability of
drugs. J Ocu Pharmacol 1:309-326
17. Prausnitz MR, Noonan JS (1998) Permeability
of cornea, sclera and conjunctiva: a literature
Impurities
in drug
substances
